This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Invitae Beheer

Beheer criteriumcontroles 1/4

De CEO Invitae is Ken Knight, benoemd in Jul2022, heeft een ambtstermijn van 2.08 jaar. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde $ 122.69. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 3.9 jaar.

Belangrijke informatie

Ken Knight

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.1yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ken Knight's beloning veranderd ten opzichte van Invitae's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	n/a	n/a	-US$800m
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$5m	US$611k	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	-US$3b
Mar 31 2022	n/a	n/a	-US$451m
Dec 31 2021	US$4m	US$500k	-US$379m
Sep 30 2021	n/a	n/a	-US$408m
Jun 30 2021	n/a	n/a	-US$313m
Mar 31 2021	n/a	n/a	-US$613m
Dec 31 2020	US$11m	US$250k	-US$602m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ken redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de UK markt.

Compensatie versus inkomsten: De vergoeding van Ken is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ken Knight (63 yo)

2.1yrs

Tenure

US$4,950,752

Compensatie

Mr. Kenneth D. Knight, also known as Ken, serves as Independent Director at Simpson Manufacturing Co., Inc. since June 21, 2021. He was the Chief Operating Officer at Invitae Corporation since June 29, 202...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Randal Scott	Co-Founder & Chairman of the Board	2.1yrs	US$256.34k	0.034% $ 38.8
Kenneth Knight	President	2.1yrs	US$4.95m	0.11% $ 122.7
Thomas Brida	General Counsel	7.6yrs	US$2.15m	0.091% $ 103.8
Ana Schrank	Chief Accounting Officer & CFO	less than a year	geen gegevens	geen gegevens
David Sholehvar	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Hoki Luk	Head of Investor Relations and Capital Markets & Corporate Development	no data	geen gegevens	geen gegevens
Shelly Guyer	Chief Sustainability Officer	3.2yrs	US$2.25m	geen gegevens
Desarie French	Chief Talent Officer	no data	geen gegevens	geen gegevens
W. Korn	Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens
Robert Guigley	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens
Jackson Finks	Director of Investor Relations & Strategic Finance	no data	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0JDB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Randal Scott	Co-Founder & Chairman of the Board	2.1yrs	US$256.34k	0.034% $ 38.8
Kenneth Knight	President	2.1yrs	US$4.95m	0.11% $ 122.7
Eric Aguiar	Lead Independent Director	13.9yrs	US$408.60k	0.0040% $ 4.6
Christine Gorjanc	Independent Director	8.8yrs	US$301.21k	0.0030% $ 3.4
William Osborne	Independent Director	1.6yrs	geen gegevens	geen gegevens
Geoffrey Crouse	Independent Director	12.4yrs	US$298.71k	0.0097% $ 11.1
Chitra Nayak	Independent Director	5.9yrs	US$278.71k	0.0030% $ 3.4
Kimber Lockhart	Independent Director	3.9yrs	US$288.71k	0.0030% $ 3.4
Jill Frizzley	Director	less than a year	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0JDB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

This company is no longer active

Invitae Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Corporation Announces Executive Changes

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Invitae Corporation Filed for Bankruptcy

Motion for Joint Administration Filed by Invitae Corporation

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$3.42 loss per share (vs US$1.27 loss in 3Q 2022)

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.78 loss per share (vs US$10.87 loss in 2Q 2022)

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Corporation Announces Executive Changes

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$13.18 loss per share (vs US$1.80 loss in FY 2021)

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Director recently sold US$115k worth of stock

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Third quarter 2022 earnings released: US$1.27 loss per share (vs US$0.91 loss in 3Q 2021)

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Invitae Corporation Reiterates Revenue Guidance for the Year 2022

Invitae Corporation to Report Q2, 2022 Results on Aug 09, 2022

Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow

Invitae Corporation Announces Executive Leadership and Board Changes

Chief Operating Officer recently sold US$108k worth of stock

Invitae Corporation Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.56 loss in 1Q 2021)

Invitae Corporation, Annual General Meeting, Jun 06, 2022

Invitae Corporation, Annual General Meeting, Jun 06, 2022

Invitae Corporation to Report Q1, 2022 Results on May 03, 2022

Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders

Invitae Announces the Launch of Invitae Digital Health

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Invitae Corporation Provides Revenue Guidance for 2022

Invitae Corporation to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.91 loss per share (vs US$0.78 loss in 3Q 2020)

Invitae Corporation (NYSE:NVTA) entered into definitive agreement to acquire Ciitizen Corporation from group of investors for approximately $350 million.

Chief Medical Officer recently sold US$540k worth of stock

Exact Sciences Approaches Invitae

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.29 loss in 2Q 2020)

Director Jason Myers has left the company